peficitinib
Trade name: Vonjo
Small moleculeexperimental
Peficitinib is a pharmaceutical drug used for the treatment of rheumatoid arthritis. It belongs to the class of drugs known as Janus kinase inhibitors. — Wikipedia
Clinical trial activity
34 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
24
Phase 2
10
Phase 3
4
Phase 4
0
Earliest trial started Jul 1, 2008 (NCT01387087)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2- Mol. weight
- 326.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaPeficitinib ↗
- ChEMBLCHEMBL3137308 ↗
Also known as
- 4-((5-hydroxy-2-adamantyl)amino)-1h-pyrrolo(2,3-b)pyridine-5-carboxamide
- asp015k
- asp015k
- asp015k
- asp015k
- asp-015k
- asp-015k
- jnj-54781532
- jnj-54781532
- peficitinib
- peficitinib
- peficitinib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04143477 | Phase 1 | Oct 31, 2019 | Astellas |
| NCT03660059 | Phase 3 | Sep 30, 2018 | Astellas |
| NCT02760342 | Phase 1 | May 1, 2016 | Astellas |
| NCT02603497 | Phase 1 | Nov 1, 2015 | Astellas |
| NCT02586194 | Phase 1 | Nov 1, 2015 | Astellas |
| NCT02531191 | Phase 1 | Jun 1, 2015 | Astellas |
| NCT02305849 | Phase 3 | Jul 25, 2014 | Astellas |
| NCT02308163 | Phase 3 | Jul 1, 2014 | Astellas |
| NCT02117505 | Phase 1 | Apr 1, 2014 | Johnson and Johnson |
| NCT02141425 | Phase 1 | Mar 1, 2014 | Astellas, Janssen Pharmaceutica NV |
| NCT01959282 | Phase 2 | Nov 1, 2013 | Johnson and Johnson |
| NCT02111317 | Phase 1 | Oct 1, 2013 | Astellas, Janssen Pharmaceutica NV |
| NCT01959399 | Phase 1 | May 1, 2013 | Astellas, Janssen Pharmaceutica NV |
| NCT01929577 | Phase 1 | May 1, 2013 | Astellas, Janssen Pharmaceutica NV |
| NCT01711814 | Phase 2 | Sep 1, 2012 | Astellas, Janssen Pharmaceutica NV |
| NCT01638013 | Phase 3 | Jun 13, 2012 | Astellas |
| NCT01686217 | Phase 1 | Jun 1, 2012 | Astellas |
| NCT01554696 | Phase 2 | Jun 1, 2012 | Astellas |
| NCT01565655 | Phase 2 | Jun 1, 2012 | Astellas |
| NCT01649999 | Phase 2 | Feb 1, 2012 | Astellas |
Showing 20 of 34 trials
Page 1 / 2
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astellas | For profit | 31 | 31 | 3 | 2008 |
| Janssen Pharmaceutica NV | For profit | 5 | 0 | 2 | 2012 |
| Johnson and Johnson | For profit | 2 | 2 | 2 | 2013 |
| Pfizer | For profit | 1 | 1 | 1 | 2011 |
4 organizations
Page 1 / 1